Across TCGA pan-cancer cohorts, MIR549A RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of MIR549A’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where MIR549A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR549A is over-expressed in tumor.
LUAD and STAD are the cancer types where MIR549A tumor–normal differential expression is most reproducible.